RNTX RNTX
Company Profile ↓Company Overview
RNTX (RNTX) is a publicly traded company listed on with a market capitalization of $19.56M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of -0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -35.64% |
| 6 Months: | -44.19% |
| 3 Months: | -29.96% |
| 1 Month: | -29.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.92 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 62.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.61M | 6.87M | 5.49M | 3.96M | 5.23M |
| Operating Income | -3.94M | -5.55M | -4.23M | -4.45M | -4.59M | -4.95M | -6.43M | -7.04M | -7.76M | -9.66M | -7.50M | -6.98M | -7.31M | -7.38M | -7.92M | -7.35M | -6.88M | -4.40M | -5.03M | -4.19M | -6.99M | -6.01M | -6.79M | -8.42M | -8.04M | -6.48M | -5.01M | -1.99M | -1.98M | -7.21M | -9.04M | -6.07M | - | -5.61M | -6.87M | -5.49M | -3.96M | -5.23M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.61M | -6.87M | -5.49M | -3.96M | -5.23M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.50M | -6.82M | -5.58M | -32.68M | -5.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.92M | -5.53M | -4.22M | -4.44M | -4.56M | -4.92M | -6.26M | -6.87M | -7.59M | -9.49M | -7.43M | -7.03M | -7.21M | -7.17M | -7.75M | -7.24M | -6.75M | -4.39M | -5.02M | -4.93M | -6.97M | -5.69M | -6.70M | -8.42M | -7.99M | -6.37M | -4.78M | -1.79M | -1.83M | -7.11M | -8.94M | -5.85M | - | -5.50M | -6.82M | -5.58M | -31.97M | -5.84M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.06 | -0.07 | -1.86 | -1.76 | -1.40 | -1.05 | -0.39 | -0.40 | -0.86 | -0.45 | -0.27 | - | -0.25 | -0.28 | -0.21 | - | -0.19 |
| R&D Expense | 2.49M | 2.09M | 2.60M | 3.09M | 2.94M | 3.16M | 3.83M | 4.31M | 4.85M | 5.32M | 4.32M | 3.96M | 4.17M | 4.30M | 4.47M | 4.71M | 4.07M | 2.49M | 2.68M | 1.93M | 4.32M | 3.85M | 4.28M | 5.89M | 5.43M | 4.24M | 1.81M | 187.00K | 22.00K | 3.46M | 3.74M | 3.72M | - | 3.05M | 4.29M | 1.68M | - | 3.07M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 27.65M | 15.35M | 28.11M | 21.93M |
| Operating Income | -12.89M | -18.17M | -23.01M | -31.90M | -29.96M | -20.50M | - | -27.65M | -15.35M | -28.11M | -21.93M |
| EBITDA | - | - | - | - | - | - | - | -27.48M | -15.23M | -28.05M | -21.93M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | -27.33M | -15.68M | -64.43M | -50.58M |
| Tax Provision | - | - | - | - | - | - | - | - | 0 | -1.54M | -712.00K |
| Net Income | -12.88M | -18.12M | -22.60M | -31.55M | -29.37M | -27.33M | - | -27.33M | -15.73M | -62.88M | -49.87M |
| Diluted EPS | - | - | - | - | - | - | - | -6.02 | -3.42 | -3.51 | -1.96 |
| R&D Expense | 7.83M | 10.28M | 14.24M | 18.45M | 17.66M | 11.17M | 17.01M | 17.97M | 3.99M | 14.25M | 11.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 22.02M | 52.69M | 30.31M | 26.47M | 16.34M | - | 22.01M | 106.01M | 62.19M | 24.16M |
| Current Assets | - | - | - | - | - | - | - | - | 21.87M | 18.27M | 13.66M | 4.33M |
| Cash & Equivalents | 6.21M | 3.77M | 20.71M | 11.86M | 10.63M | 5.31M | 7.05M | - | 5.19M | 17.31M | 12.87M | 3.21M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 4.08M | 4.89M | 10.71M | 10.43M | 4.18M | - | 3.38M | 99.12M | 52.80M | 52.24M |
| Current Liabilities | - | - | 4.07M | 4.89M | 5.37M | 5.84M | 3.96M | - | 3.38M | 4.38M | 5.75M | 6.18M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 162.00K | 33.00K | 48.00K | 0 | - |
| Total Equity | -82.04M | -94.32M | -111.81M | 47.80M | 19.60M | 16.05M | 12.16M | - | 18.62M | 6.89M | 9.39M | -28.09M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 4.54M | 4.89M | 21.67M | 27.55M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -20.53M | -27.93M | -26.47M | -20.48M | - | -24.86M | -19.81M | -22.29M | -19.36M |
| Investing Cash Flow | - | -38.91M | 24.69M | -2.81M | 6.41M | -35.92M | 26.46M | 16.20M | 0 | - |
| Financing Cash Flow | - | 50.59M | 2.52M | 23.96M | 15.80M | - | 0 | 15.79M | 17.82M | 9.76M |
| Capital Expenditure | -94.00K | -142.00K | -4.42M | -151.00K | -5.00K | -157.00K | - | - | - | - |
| Free Cash Flow | - | -20.67M | -32.35M | -26.62M | -20.48M | - | -24.86M | -19.81M | -22.29M | -19.36M |
| Net Change in Cash | - | - | - | - | - | - | 1.59M | 12.18M | -4.47M | -9.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 13.7% | 16.2% | -47.3% | -161.0% | -183.0% | -224.7% | - | -146.7% | -228.4% | -669.9% | 177.6% |
| ROCE % | - | -101.2% | -48.1% | -127.9% | -145.2% | -165.5% | - | -148.5% | -15.1% | -49.8% | -122.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNTX
Rein's Inhaled LTI-03 Reduced Lung-Scarring Markers After 14 Days - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQOUoxa3kzZUNEYU1ibzlOVlIzRHlsaFhZTHB3czJhUzE0ZnJYZDdJTU1wcmxDZGw5cUdGZlBHc0pTazhXNV9YWURmUkdrUzI2YzVOb3JQTlJ6YkV2YU5oNnR4d2J0Tmh1Y3IyU2Rsc0N1YUoyUWxLd0o0Wi1HVHVhaWt1VkhnZjhvY0s5UW…
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPMkhYYUpmRVZfUjFmWmZld3hTTEJNQlZTSnJTa19XbVZqTWNycTllOHVzRTlodXFSVXU5R19KVUFWVTFlYVBZUXNBXzFQZDVxYTNCcW1oNV9aV2tBVFlNbDdJa2lGcVRyZFUxOGRmbTl1X1hrN25ndU9RSFdNVDl1OEdLeXl3MGxmUHRFT2…
RNTX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9GZkJMUDVyY0lwcFZ1eEQ1OXZlUmNCdWtMMWZpTFV0VEN5QTdiMXJjcjh0ZDN0TVMwLXNveHNqdEhNUGFwTUJCbk5vLUlQYWQ1ZXctMmxnQnpvd0wweldhQWlvRDkxbWNORVRfZ3VoWVMwQTNjVFNDY1VR?oc=5" target="_blank">RNT…
RNTX|Rein Therapeutics Inc|Price:0.737|Chg%:-0.031 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1aYm92MFUzamlVVFB4OTlKcjlGUE05dUc0aXl5bnZ6bVhnb0lqNE1zYVpYSENmb1ZUY3B2VTRfb0ZZVmJBNFhCaTNmd1BqaG9uSTRPZ0ZXZ19tdXp0Y184UVNjc0NUTVV6OVd3QzZn?oc=5" target="_blank">RNTX|Rein Therapeut…
RNTX Initiates Coverage On by Maxim Group -- Rating Set to Buy - GuruFocus
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNdFlfbElSa1pRQmhBTlV3aDc3b21NeUx6Zk1jS0k4M3VyT3F5WVZCRGl6bXZfbDIyQkFkZDVUbXpJbkRqSTlJTUQzakdqV0hwcVF3ZS1hTTRaS2k4b0UzWVpFRkdWMS1wbmdEUGU1UXAtbGZmWmkwT3VKSmxxQWNVREpXZnpkcGs1Y09PUV…
RNTX Stock Slides As Traders Eye Heavy Losses - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9HNlVIYnZOTnRRTV9oWnUwZ2h0YUlDelJOOGR4QVBTVmFzeHQ1dkV1amx0NDd6R192RW1ua01kcHQ0d3JGSXFidzNucGZ6ZVFQeTBFN1EwMmhrOTFZb2dEcFZNaHdmMnBEdmNZdnNXLWlaYlY4MzZ2Smd1cGJQdw?oc=5" target="_blan…
RNTX — Frequently Asked Questions
What is the current share price of RNTX?
As of 2026-08-05 17:25 PDT, RNTX trades at $0.71 on NASDAQ/NYSE. Its 52-week range is $0.71 to $1.88.
What is the market capitalisation of RNTX?
RNTX has a market capitalisation of $19.56M on NASDAQ/NYSE.
What is the P/E ratio of RNTX?
RNTX trades at a trailing price-to-earnings (P/E) ratio of -0.36. Its price-to-book (P/B) ratio is -0.70.
Is RNTX a good stock to buy?
This page provides a data-driven analysis of RNTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.